James B Lewin

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 15

Top Topics

Top Venues

Neurology and therapy

Advances in therapy

Journal of medical economics

This page only lists publications with an associated author ORCID identifier.

Publications

Tammy Jiang, Mathura Shanmugasundaram, Ivan Božin, Mark S Freedman, James B Lewin, Changyu Shen, Tjalf Ziemssen, Douglas L Arnold
Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons. Journal of comparative effectiveness research (2024)
Barry A Singer, Sibyl Wray, Mark Gudesblatt, Barbara Bumstead, Tjalf Ziemssen, Ashley Bonnell, Matthew Scaramozza, Seth Levin, Mathura Shanmugasundaram, Hailu Chen, Jason P Mendoza, James B Lewin, Sai L Shankar
Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing-Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study. Neurology and therapy (2024)
Barry A Singer, Sibyl Wray, Mark Gudesblatt, Barbara Bumstead, Tjalf Ziemssen, Ashley Bonnell, Matthew Scaramozza, Seth Levin, Mathura Shanmugasundaram, Hailu Chen, Jason P Mendoza, James B Lewin, Sai L Shankar
Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing-Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study. Neurology and therapy 13 (4) (2024)
James D Bowen, Jessica Stulc, Samuel F Hunter, Hailu Chen, James B Lewin, Matthew Scaramozza, Ivan Božin, Florian Then Bergh
Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: NEDA-3 After Re-Baselining in the Phase 3 EVOLVE-MS-1 Study. Advances in therapy 41 (8) (2024)
James D Bowen, Jessica Stulc, Samuel F Hunter, Hailu Chen, James B Lewin, Matthew Scaramozza, Ivan Božin, Florian Then Bergh
Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: NEDA-3 After Re-Baselining in the Phase 3 EVOLVE-MS-1 Study. Advances in therapy 41 (8) (2024)
James D Bowen, Jessica Stulc, Samuel F Hunter, Hailu Chen, James B Lewin, Matthew Scaramozza, Ivan Božin, Florian Then Bergh
Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: NEDA-3 After Re-Baselining in the Phase 3 EVOLVE-MS-1 Study. Advances in therapy (2024)
James D Bowen, Jessica Stulc, Samuel F Hunter, Hailu Chen, James B Lewin, Matthew Scaramozza, Ivan Božin, Florian Then Bergh
Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: NEDA-3 After Re-Baselining in the Phase 3 EVOLVE-MS-1 Study. Advances in therapy 41 (8) (2024)
Barry A Singer, Sibyl Wray, Mark Gudesblatt, Barbara Bumstead, Tjalf Ziemssen, Ashley Bonnell, Matthew Scaramozza, Seth Levin, Mathura Shanmugasundaram, Hailu Chen, Jason P Mendoza, James B Lewin, Sai L Shankar
Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing-Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study. Neurology and therapy 13 (4) (2024)
Barry A Singer, Sibyl Wray, Mark Gudesblatt, Barbara Bumstead, Tjalf Ziemssen, Ashley Bonnell, Matthew Scaramozza, Seth Levin, Mathura Shanmugasundaram, Hailu Chen, Jason P Mendoza, James B Lewin, Sai L Shankar
Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing-Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study. Neurology and therapy 13 (4) (2024)
Daniel Bandari, Meagan Adamson, Michelle Bowman, Amparo Gutierrez, Amod S Athavale, Bhagyashree Oak, Nandini Hadker, Filipe Branco, Caroline Geremakis, James B Lewin, Sai L Shankar
Real-world treatment preferences among health care providers in the United States in selecting disease modifying therapies for patients with multiple sclerosis: a discrete choice experiment. Journal of medical economics (2023)
Lilyana Amezcua, Yang Mao-Draayer, Wendy S Vargas, Rebecca Farber, Sara Schaefer, Filipe Branco, Sarah M England, Nicholas Belviso, James B Lewin, Jason P Mendoza, Sai L Shankar, null null
Efficacy of Dimethyl Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE Studies. Neurology and therapy (2023)
Brittney Lager, Jacob Liseno, Ivan Božin, Sarah M England, Sai L Shankar, Jason P Mendoza, James B Lewin
Response to Letter to the Editor Regarding "Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis". Neurology and therapy (2023)
Tammy Jiang, Tjalf Ziemssen, Sibyl Wray, Changyu Shen, Karin Söderbärg, James B Lewin, Ivan Božin, Mark S Freedman
Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis. CNS drugs (2023)
Brittney Lager, Jacob Liseno, Ivan Božin, Sarah M England, Sai L Shankar, Jason P Mendoza, James B Lewin
Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis. Neurology and therapy (2022)
Jacob Liseno, Brittney Lager, Catherine Miller, Sai L Shankar, Jason P Mendoza, James B Lewin
Multiple Sclerosis Patients Treated With Diroximel Fumarate in the Real-World Setting Have High Rates of Persistence and Adherence. Neurology and therapy 10 (1) (2021)